A look at how the rise of GLP-1 drugs is changing which research samples scientists are buying. Details are thin beyond the headline.
Recap by typeshit. Full story at Technology Networks.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
In rat studies, Pratt found GLP-1 activation in a reward region blunted opioid-driven binge eating. His lab is now looking at another gut peptide, GRP.
A study of 300 million Epic records at the AAO meeting found an early risk signal flipped once diabetes, blood pressure and cholesterol were accounted for.
Loading…